← Back to Search

Cannabinoid

Cannabidiol for Opioid Use Disorder and Chronic Pain

Phase < 1
Recruiting
Led By Joao De'Aquino, M.D.
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Having chronic pain, uniformly operationalized as grade II (high-intensity) non-cancer musculoskeletal pain for ≥ 6 months
Diagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks
Awards & highlights

Study Summary

This trial will test the effects of CBD on social anxiety.

Who is the study for?
This trial is for adults aged 18-70 with chronic high-intensity musculoskeletal pain and opioid use disorder, who are stable on opioid maintenance treatment. Participants must be able to consent in English, not have major medical issues or unstable psychiatric conditions, and women must not be pregnant or breastfeeding.Check my eligibility
What is being tested?
The study tests the effects of Cannabidiol (CBD) at different doses (1200mg, 800mg, and 400mg) compared to a saline placebo in managing chronic pain and opioid dependency. It's a double-blind study where neither participants nor researchers know who gets CBD or placebo during four sessions after an initial screening.See study design
What are the potential side effects?
While specific side effects aren't listed here, CBD can commonly cause tiredness, diarrhea, changes in appetite/weight. Since it's being tested against saline (a harmless substance), any additional side effects observed could help understand CBD's impact.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had severe non-cancer related muscle or bone pain for 6 months or more.
Select...
I am diagnosed with opioid use disorder and am on methadone or buprenorphine.
Select...
I am not pregnant, not breastfeeding, and using birth control.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Quantitative Sensory Testing (QST)
Systematic Assessment for Treatment Emergent Events (SAFTEE)

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: CBD 400mgActive Control1 Intervention
CBD 400 mg
Group II: CBD 1200mgActive Control1 Intervention
CBD 1200mg
Group III: CBD 800mgActive Control1 Intervention
CBD 800mg
Group IV: SalinePlacebo Group1 Intervention
saline

Find a Location

Who is running the clinical trial?

VA Connecticut Healthcare SystemFED
82 Previous Clinical Trials
6,650 Total Patients Enrolled
3 Trials studying Chronic Pain
320 Patients Enrolled for Chronic Pain
Yale UniversityLead Sponsor
1,870 Previous Clinical Trials
2,742,983 Total Patients Enrolled
14 Trials studying Chronic Pain
2,690 Patients Enrolled for Chronic Pain
National Institute on Drug Abuse (NIDA)NIH
2,496 Previous Clinical Trials
2,623,865 Total Patients Enrolled
57 Trials studying Chronic Pain
83,430 Patients Enrolled for Chronic Pain

Media Library

Cannabidiol (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04587791 — Phase < 1
Chronic Pain Research Study Groups: CBD 400mg, Saline, CBD 1200mg, CBD 800mg
Chronic Pain Clinical Trial 2023: Cannabidiol Highlights & Side Effects. Trial Name: NCT04587791 — Phase < 1
Cannabidiol (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04587791 — Phase < 1
~8 spots leftby Feb 2025